Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Kun WangXiaoyong DaiAlbert YuChunyan FengKewei LiuLaiqiang HuangPublished in: Journal of experimental & clinical cancer research : CR (2022)
Our results indicate that biologically targeted degradation of FOXM1 is an attractive therapeutic strategy, and antagonist peptide-containing FOXM1-PROTACs as both degrader and inhibitor of FOXM1 could be developed as a safe and promising drug for FOXM1-overexpressed cancer therapy.